SAN

Sanofi (SAN)

Sanofi

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:EU:SAN

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/26	02 : 32	GlobeNewswire Inc.	Press Release: Availability of the Q2 2024 Aide-mémoire	EU:SAN	Sanofi
2024/06/26	02 : 32	GlobeNewswire Inc.	Communiqué de presse : Mise en ligne du document « Aide-mémoire Q2 2024 »	EU:SAN	Sanofi
2024/06/21	16 : 30	GlobeNewswire Inc.	Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee	EU:SAN	Sanofi
2024/06/21	16 : 30	GlobeNewswire Inc.	Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee	EU:SAN	Sanofi
2024/06/21	16 : 30	GlobeNewswire Inc.	Communiqué de presse : Audrey Duval Derveloy nommée Directrice Affaires Corporate Groupe, membre du Comité exécutif de Sanofi	EU:SAN	Sanofi
2024/06/21	14 : 00	GlobeNewswire Inc.	Communiqué de presse : ISTH : De nouvelles données sur ALTUVIIIO et le fitusiran confortent le leadership de Sanofi dans le traitement de l’hémophilie	EU:SAN	Sanofi
2024/06/21	14 : 00	GlobeNewswire Inc.	Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran	EU:SAN	Sanofi
2024/06/21	14 : 00	GlobeNewswire Inc.	Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran	EU:SAN	Sanofi
2024/06/20	21 : 00	GlobeNewswire Inc.	Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa	EU:SAN	Sanofi
2024/06/20	21 : 00	GlobeNewswire Inc.	Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa	EU:SAN	Sanofi
2024/06/20	21 : 00	GlobeNewswire Inc.	Communiqué de presse : Sanofi et Biovac pionniers de la production de vaccins contre la polio en Afrique	EU:SAN	Sanofi
2024/06/13	03 : 19	GlobeNewswire Inc.	Sanofi: Information concerning the total number of voting rights and shares – May 2024	EU:SAN	Sanofi
2024/06/13	03 : 19	GlobeNewswire Inc.	Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2024	EU:SAN	Sanofi
2024/06/04	05 : 15	GlobeNewswire Inc.	Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3	EU:SAN	Sanofi
2024/06/04	05 : 15	GlobeNewswire Inc.	Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3	EU:SAN	Sanofi
2024/06/04	05 : 15	GlobeNewswire Inc.	Communiqué de presse : ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients […]	EU:SAN	Sanofi
2024/05/31	19 : 00	GlobeNewswire Inc.	Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan	EU:SAN	Sanofi
2024/05/31	19 : 00	GlobeNewswire Inc.	Communiqué de presse : Sanofi lance son plan mondial 2024 d’actionnariat salarié	EU:SAN	Sanofi
2024/05/31	19 : 00	GlobeNewswire Inc.	Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan	EU:SAN	Sanofi
2024/05/31	14 : 05	GlobeNewswire Inc.	Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO	EU:SAN	Sanofi
2024/05/31	14 : 05	GlobeNewswire Inc.	Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD	EU:SAN	Sanofi
2024/05/31	14 : 05	GlobeNewswire Inc.	Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD	EU:SAN	Sanofi
2024/05/31	14 : 05	GlobeNewswire Inc.	Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD	EU:SAN	Sanofi
2024/05/31	14 : 00	GlobeNewswire Inc.	Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation	EU:SAN	Sanofi
2024/05/31	14 : 00	GlobeNewswire Inc.	Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation	EU:SAN	Sanofi
2024/05/31	14 : 00	GlobeNewswire Inc.	Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2	EU:SAN	Sanofi
2024/05/30	22 : 01	GlobeNewswire Inc.	Press Release: Sanofi completes acquisition of Inhibrx, Inc.	EU:SAN	Sanofi
2024/05/30	22 : 01	GlobeNewswire Inc.	Communiqué de presse : Sanofi finalise l’acquisition d’Inhibrx, Inc.	EU:SAN	Sanofi
2024/05/30	22 : 01	GlobeNewswire Inc.	Press Release: Sanofi completes acquisition of Inhibrx, Inc.	EU:SAN	Sanofi
2024/05/27	14 : 00	GlobeNewswire Inc.	Communiqué de presse : La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantation	EU:SAN	Sanofi